Inotuzumab Ozogamicin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Inotuzumab Ozogamicin. Educational only — not medical advice.
Labeled uses
BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older .
Source: FDA labeling via NIH DailyMed (set cc7014b1…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.